Thanos Maroglou is a serial entrepreneur contributing scientific, management and business experience both in health care and agricultural industries. For over 30 years, he held senior management roles or co-founded multiple companies with profitable exits.
Dr. Maroglou is currently the CEO and co-founder of Rescindo Therapeutics, a target and drug discovery company for human genetic diseases. Some of his prior roles have included: CBO for Cato Research and BioVentures, a CRO and strategic investment company; VP of Business Development for Chimerix Inc, an antiviral company that went public in 2013; President of Ercole Biotech that was acquired by Serepta Therapeutics and recently had the first DMD drug approved; and VP of Project Management for Paradigm Genetics that was functional genomics company and went public in 2000.
Through his investment company, Symphonia Partners, he has worked with multiple companies, setting strategic direction and doing business deals in various sectors. Dr. Maroglou enjoys serving as a Board of Director member for companies, helping them grow, mature and succeed.
Dr. Maroglou began his career and spent 14 years with E.I. DuPont Ag in positions of increased responsibility in research, manufacturing, and business. He holds a BSc and PhD in Chemical Engineering from the University of Birmingham, UK.